~~<i id='9002D3FB80'><strike id='9002D3FB80'><tt id='9002D3FB80'><pre id='9002D3FB80'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

explore

author：comprehensive 2025-09-27 09:38:05 - browse：4187

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： The woman behind the Dana Farber

entertainment

explore

focus

explore

entertainment

AdobeOneofthehardestpartsaboutgettinganX-rayoraCTscanisthewait.Sometimesittakesdays,orevenweeks,form

WSS

Does Paxlovid work in people vaccinated against Covid

The woman behind the Dana Farber

STAT letters to the editor on burnt

STAT letters to the editor on burnt

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

STAT letters to the editor on burnt

focus

explore

entertainment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Gene therapy denied for Afghan refugee whose father aided U.S.

At least 13 dead in Texas as scorching temps continue

Allen Institute goes after foundational questions, CEO Costa says

The cancer drug shortage isn’t new — and neither are the solutions

Congenital heart disease patients face new threat of heart failure

After affirmative action ruling, medical educators look to 'holistic review'

Radiology is caught between AI's potential and concern for patients

After affirmative action ruling, medical educators look to 'holistic review'

Study suggests new cause of Down syndrome: cells linked to aging

explore

Pfizer plans to depart BIO

Stories you might have missed in 2023: health, science, medicine

Gene therapy denied for Afghan refugee whose father aided U.S.

JPM pitch from hospitals? Revenue streams outside of patient care

Chemotherapy shortages won’t get better under Biden’s latest plan

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

focus

explore

entertainment

entertainment